A Phase 3 interventional study of NOVA22007 ''Ciclosporin'' and Placebo in Vernal Keratoconjunctivitis, sponsored by Santen SAS. Completed at 46 sites in 11 countries. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-03-28.
Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day in patients with severe vernal keratoconjunctivitis after 4 months of treatment.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
This study's enrollment of 169 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Browse Conjunctivitis, Allergic studies →Santen SAS is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
First submitted after Santen Inc. became part of Santen Pharmaceutical Co., Ltd..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).
Drug: NOVA22007 ''Ciclosporin''
One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.
Drug: NOVA22007 ''Ciclosporin'' · Drug: Placebo
One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).
Drug: Placebo
Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months
Efficacy was assessed every month during the 4-month treatment phase and compared with Baseline using a composite criterion based on: * Keratitis assessed by the modified Oxford scale (7-point ordinal scale, score 0, 0.5, and 1 to 5). On this modified scale, the score 0 corresponded to no staining dots and the score 0.5 to three or less staining dots. A CFS grade of 0 represented complete corneal clearing. * Need for rescue medication. * Occurrence of corneal ulceration. An efficacy score was calculated as follows: Patient's score at month X = CFS (Baseline) - CFS (Month X) + penalty (ies) Penalty for rescue medication: -1 (per course, with a maximum of 2 courses between 2 scheduled visits) Penalty for corneal ulceration: -1 (per occurrence). A positive value indicated improvement. The maximum CFS is five and the minimum cannot be set due to the number of rescue medication and ulceration which decreases the penalty adjusted CFS.
Time frame: over the 4 months
Best Corrected Distance Visual Acuity (BCDVA) in 4-month Randomized Period I
Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicates poor vision.
Time frame: Up to Month4
Best Corrected Distance Visual Acuity (BCDVA) in 8-month Safety FU Period- Period II
Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicate poor vision.
Time frame: Up to Month12
Number of Courses of Rescue Medication in Period I
Use of rescue medication: the total number of topical corticosteroid courses was assessed at each visit during the 4-month efficacy evaluation treatment period.
Time frame: Up to Month4
| Milestone | High Dose Regimen | Low Dose Regimen | Placebo |
|---|---|---|---|
| Started | 57 | 54 | 58 |
| Completed | 51 | 43 | 49 |
| Not completed | 6 | 11 | 9 |
| Milestone | High Dose Regimen | Low Dose Regimen | Placebo |
|---|---|---|---|
| Started | 72 | 70 | 0 |
| Completed | 72 | 70 | 0 |
| Not completed | 0 | 0 | 0 |
Efficacy was assessed every month during the 4-month treatment phase and compared with Baseline using a composite criterion based on: * Keratitis assessed by the modified Oxford scale (7-point ordinal scale, score 0, 0.5, and 1 to 5). On this modified scale, the score 0 corresponded to no staining dots and the score 0.5 to three or less staining dots. A CFS grade of 0 represented complete corneal clearing. * Need for rescue medication. * Occurrence of corneal ulceration. An efficacy score was calculated as follows: Patient's score at month X = CFS (Baseline) - CFS (Month X) + penalty (ies) Penalty for rescue medication: -1 (per course, with a maximum of 2 courses between 2 scheduled visits) Penalty for corneal ulceration: -1 (per occurrence). A positive value indicated improvement. The maximum CFS is five and the minimum cannot be set due to the number of rescue medication and ulceration which decreases the penalty adjusted CFS.
| Penalties Adjusted CFS Score | High Dose Regimen | Low Dose Regimen | Placebo |
|---|---|---|---|
| Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months | 2.06 ± 1.44 | 1.93 ± 1.37 | 1.34 ± 1.22 |
Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicates poor vision.
| letters | LogMAR - High Dose Regimen | LogMAR - Low Dose Regimen | LogMAR-Placebo | Change From Baseline in LogMAR- High Dose | Change From Baseline in LogMAR- Low Dose | Change From Baseline in LogMAR- Placebo |
|---|---|---|---|---|---|---|
| Analysis Eye-Baseline | 0.293 ± 0.297 | 0.209 ± 0.284 | 0.302 ± 0.347 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Analysis Eye-Month 1 | 0.263 ± 0.292 | 0.160 ± 0.241 | 0.285 ± 0.362 | -0.036 ± 0.187 | -0.058 ± 0.199 | -0.027 ± 0.182 |
| Analysis Eye-Month 2 | 0.221 ± 0.251 | 0.146 ± 0.214 | 0.331 ± 0.352 | -0.071 ± 0.191 | -0.073 ± 0.202 | 0.003 ± 0.233 |
| Analysis Eye-Month 3 | 0.172 ± 0.235 | 0.110 ± 0.204 | 0.273 ± 0.318 | -0.110 ± 0.173 | -0.089 ± 0.233 | -0.066 ± 0.229 |
| Analysis Eye-Month 4 | 0.149 ± 0.244 | 0.097 ± 0.203 | 0.237 ± 0.308 | -0.127 ± 0.165 | -0.110 ± 0.233 | -0.109 ± 0.211 |
| Analysis Eye-Month 4/ Early Termination | 0.158 ± 0.249 | 0.114 ± 0.212 | 0.217 ± 0.295 | -0.135 ± 0.220 | -0.091 ± 0.257 | -0.097 ± 0.210 |
Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicate poor vision.
| letters | LogMAR - High Dose Regimen | LogMAR - Placebo | LogMAR-Total | Change From Baseline in LogMAR- High Dose | Change From Baseline in LogMAR- Placebo | Change From Baseline in LogMAR- Total |
|---|---|---|---|---|---|---|
| Analysis Eye-Baseline (Month 4) | 0.152 ± 0.246 | 0.250 ± 0.317 | 0.181 ± 0.270 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Analysis Eye-Month 6 | 0.128 ± 0.230 | 0.258 ± 0.359 | 0.168 ± 0.280 | -0.024 ± 0.114 | -0.017 ± 0.143 | -0.022 ± 0.122 |
| Analysis Eye-Month 8 | 0.141 ± 0.228 | 0.222 ± 0.324 | 0.165 ± 0.261 | -0.015 ± 0.136 | -0.029 ± 0.155 | -0.019 ± 0.141 |
| Analysis Eye-Month 10 | 0.141 ± 0.222 | 0.207 ± 0.325 | 0.160 ± 0.257 | -0.014 ± 0.149 | -0.044 ± 0.128 | -0.023 ± 0.143 |
| Analysis Eye-Month 12 | 0.134 ± 0.214 | 0.220 ± 0.363 | 0.160 ± 0.268 | -0.020 ± 0.152 | -0.030 ± 0.172 | -0.023 ± 0.157 |
| Analysis Eye-Month 12/ Early Termination | 0.136 ± 0.212 | 0.220 ± 0.363 | 0.161 ± 0.266 | -0.016 ± 0.154 | -0.030 ± 0.172 | -0.020 ± 0.158 |
Use of rescue medication: the total number of topical corticosteroid courses was assessed at each visit during the 4-month efficacy evaluation treatment period.
| Participants | High Dose Regimen | Low Dose Regimen | Placebo |
|---|---|---|---|
| Month1, zero course | 51 | 41 | 44 |
| Month 1, one course | 3 | 7 | 11 |
| Month1, two courses | 0 | 2 | 2 |
| Month2, zero course | 45 | 43 | 38 |
| Month 2, one course | 6 | 2 | 11 |
| Month 2, two courses | 2 | 2 | 3 |
| Month3, zero course | 43 | 42 | 34 |
| Month3, one course | 7 | 2 | 12 |
| Month 3, two courses | 1 | 2 | 4 |
| Month4, zero course | 42 | 41 | 38 |
| Month4, one course | 6 | 2 | 8 |
| Month 4, two courses | 2 | 1 | 2 |
| Month 4/Early Termination, zero course | 46 | 46 | 43 |
| Month 4/Early Termination, one course | 7 | 5 | 11 |
| Month 4/Early Termination, two courses | 3 | 3 | 4 |
Collected over From the time the informed consent form was signed until the last study visit at Month 12.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| .1% QID (4 Months) Plus .1% QID (8 Months Safety Follow-up) | — | 3/50 (6%) | 29/50 (58%) |
| Vehicle QID (4 Months) Plus .1% QID (8 Months Safety Follow-up) | — | 0/22 (0%) | 13/22 (59.1%) |
| Total High Dose | — | 3/72 (4.2%) | 42/72 (58.3%) |
| .1% BID + Vehicle BID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up) | — | 1/44 (2.3%) | 24/44 (54.5%) |
| Vehicle QID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up) | — | 0/26 (0%) | 11/26 (42.3%) |
| Total Low Dose | — | 1/70 (1.4%) | 35/70 (50%) |
| Event | .1% QID (4 Months) Plus .1% QID (8 Months Safety Follow-up) | Vehicle QID (4 Months) Plus .1% QID (8 Months Safety Follow-up) | Total High Dose | .1% BID + Vehicle BID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up) | Vehicle QID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up) | Total Low Dose |
|---|---|---|---|---|---|---|
| Head injuryInjury, poisoning and procedural complications | 0/50 | 0/22 | 0/72 | 1/44 | 0/26 | 1/70 |
| Tibia fractureInjury, poisoning and procedural complications | 1/50 | 0/22 | 1/72 | 0/44 | 0/26 | 0/70 |
| Ulcerative keratitisEye disorders | 1/50 | 0/22 | 1/72 | 0/44 | 0/26 | 0/70 |
| PhimosisCongenital, familial and genetic disorders | 1/50 | 0/22 | 1/72 | 0/44 | 0/26 | 0/70 |
| Event | .1% QID (4 Months) Plus .1% QID (8 Months Safety Follow-up) | Vehicle QID (4 Months) Plus .1% QID (8 Months Safety Follow-up) | Total High Dose | .1% BID + Vehicle BID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up) | Vehicle QID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up) | Total Low Dose |
|---|---|---|---|---|---|---|
| Instillation site painGeneral disorders | 6/50 | 4/22 | 10/72 | 5/44 | 0/26 | 5/70 |
| Eye pruritusEye disorders | 0/50 | 3/22 | 3/72 | 0/44 | 1/26 | 1/70 |
| Instillation site pruritusGeneral disorders | 2/50 | 3/22 | 5/72 | 4/44 | 0/26 | 4/70 |
| NasopharyngitisInfections and infestations | 3/50 | 0/22 | 3/72 | 5/44 | 1/26 | 6/70 |
| Ocular hyperaemiaEye disorders | 2/50 | 2/22 | 4/72 | 0/44 | 1/26 | 1/70 |
| Ocular discomfortEye disorders | 0/50 | 2/22 | 2/72 | 0/44 | 0/26 | 0/70 |
| Instillation site erythemaGeneral disorders | 1/50 | 2/22 | 3/72 | 2/44 | 0/26 | 2/70 |
| InfluenzaInfections and infestations | 4/50 | 0/22 | 4/72 | 0/44 | 0/26 | 0/70 |
| HeadacheNervous system disorders | 4/50 | 1/22 | 5/72 | 0/44 | 1/26 | 1/70 |
| PharyngitisEye disorders | 2/50 | 0/22 | 2/72 | 0/44 | 2/26 | 2/70 |
One participant from the High dose regimen withdrew at the first week of randomization and not related to study medication.
| Age, Customized(years) | High Dose Regimen | Low Dose Regimen | Placebo | Total |
|---|---|---|---|---|
| Children (4-18 years) | 9.1 ± 3.3 | 9.6 ± 3.4 | 8.9 ± 3.2 | 9.2 ± 3.3 |
| Sex: Female, Male(Participants) | High Dose Regimen | Low Dose Regimen | Placebo | Total |
|---|---|---|---|---|
| Female | 12 | 12 | 12 | 36 |
| Male | 44 | 42 | 46 | 132 |
| Race (NIH/OMB)(Participants) | High Dose Regimen | Low Dose Regimen | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 11 | 11 | 13 | 35 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 5 | 2 | 10 |
| White | 40 | 38 | 41 | 119 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 | 4 |
The record gives a start of Apr 2013, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2022, 6 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NOVA22007